Recordati Takes On New Debt To Fund $825m Enjaymo Buy
Once the deal with Sanofi closes, the rare disease drug will become one of Recordati’s fastest forecast sellers.
Once the deal with Sanofi closes, the rare disease drug will become one of Recordati’s fastest forecast sellers.